Checkpoint blockade and microsatellite instability

Abstract

Blockade of immune checkpoints such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1) shows promise in patients with cancer. Inhibitory antibodies directed at these receptors have been shown to break immune tolerance and promote anti-tumor immunity. These agents work particularly well in patients with a certain category of tumor. Such tumors may be particularly susceptible to treatment because of the multitude of neoantigens which they produce.

We claim: 
     
         1 . A method of treating endometrial cancer in a human patient, the method comprising:
 testing or having tested a biological sample obtained from a patient having endometrial cancer, thereby determining that the patient's endometrial cancer is microsatellite instability high or DNA mismatch repair deficient; and   in response to determining that the endometrial cancer is microsatellite instability high or DNA mismatch repair deficient, treating the patient determined to have microsatellite instability high or DNA mismatch repair deficient endometrial cancer with a therapeutically effective amount of an anti-PD-1 antibody.   
     
     
         2 . The method of  claim 1 , wherein the biological sample is tumor tissue. 
     
     
         3 . The method of  claim 1 , wherein the biological sample is a body fluid. 
     
     
         4 . The method of  claim 1 , wherein the endometrial cancer is determined to be microsatellite instability high. 
     
     
         5 . The method of  claim 1 , wherein the endometrial cancer is determined to be DNA mismatch repair deficient. 
     
     
         6 . The method of  claim 1 , wherein the patient had previously been treated with a prior cancer therapy drug and the patient's endometrial cancer had progressed after the patient was treated with the prior cancer therapy drug. 
     
     
         7 . The method of  claim 1 , further comprising testing or having tested the patient for progression of the endometrial cancer after the treatment. 
     
     
         8 . The method of  claim 1 , wherein the endometrial cancer is metastatic. 
     
     
         9 . The method of  claim 1 , wherein the anti-PD-1 antibody is nivolumab. 
     
     
         10 . A method of reducing the risk of endometrial cancer progression or increasing overall survival in a human patient having endometrial cancer, the method comprising:
 testing, or having tested, a biological sample obtained from a patient having endometrial cancer thereby determining that the patient's endometrial cancer is microsatellite instability high or DNA mismatch repair deficient; and   in response to determining that the endometrial cancer is microsatellite instability high or DNA mismatch repair deficient, treating the patient determined to have microsatellite instability high or DNA mismatch repair deficient endometrial cancer with a therapeutically effective amount of an anti-PD-1 antibody.   
     
     
         11 . The method of  claim 10 , wherein the biological sample is a tumor tissue sample from the patient. 
     
     
         12 . The method of  claim 10 , wherein the biological sample is a body fluid from the patient. 
     
     
         13 . The method of  claim 10 , wherein the endometrial cancer is determined to be microsatellite instability high. 
     
     
         14 . The method of  claim 10 , wherein the endometrial cancer is determined to be DNA mismatch repair deficient. 
     
     
         15 . The method of  claim 10 , wherein the patient had previously been treated with a prior cancer therapy drug and the patient's endometrial cancer had progressed after the patient was treated with the prior cancer therapy drug. 
     
     
         16 . The method of  claim 10 , further comprising testing or having tested the patient for progression of the endometrial cancer after the treatment. 
     
     
         17 . The method of  claim 10 , wherein the endometrial cancer is metastatic cancer. 
     
     
         18 . The method of  claim 10 , wherein the anti-PD-1 antibody is nivolumab. 
     
     
         19 . The method of  claim 10 , wherein the method reduces the risk of endometrial cancer progression. 
     
     
         20 . The method of  claim 10 , wherein the method increases overall survival. 
     
     
         21 . The method of  claim 18 , wherein the method reduces the risk of endometrial cancer progression. 
     
     
         22 . The method of  claim 18 , wherein the method increases overall survival.